Tolerability of escalating doses of AG 013 in patients with ulcerative oral mucositis due to induction chemotherapy for head and neck cancer

Trial Profile

Tolerability of escalating doses of AG 013 in patients with ulcerative oral mucositis due to induction chemotherapy for head and neck cancer

Completed
Phase of Trial: Phase I

Latest Information Update: 26 Nov 2013

At a glance

  • Drugs AG 013 (Primary)
  • Indications Stomatitis
  • Focus Adverse reactions
  • Most Recent Events

    • 26 Nov 2013 New trial record
    • 24 Sep 2013 Results published in Cancer.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top